Page last updated: 2024-10-31

moclobemide and Carcinoma, Hepatocellular

moclobemide has been researched along with Carcinoma, Hepatocellular in 1 studies

Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.
moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.

Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Huang, YH1
Yeh, CT1

Other Studies

1 other study available for moclobemide and Carcinoma, Hepatocellular

ArticleYear
Anticancer Effects of Antidepressants in Hepatocellular Carcinoma Cells.
    Anticancer research, 2023, Volume: 43, Issue:3

    Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Carcinoma, Hepatocellular; Humans;

2023